Infectious Disease
115
20
22
62
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Research Maturity
62 completed trials (54% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.6%
3 terminated out of 115 trials
95.4%
+8.9% vs benchmark
7%
8 trials in Phase 3/4
16%
10 of 62 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 62 completed trials
Clinical Trials (115)
Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
An International Observational Study of Adults With Acute Infection
Contribution of a Video Support to Inform the Patient Before a Complementary Examination in Infectious Diseases
Infectious Diseases Experts as Part of the Antibiotic Stewardship Team in Primary Care
L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients)
A Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor
A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients)
Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers
A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel
Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients
CytOSorb TreatMent Of Critically Ill PatientS Registry
Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
Vitality in Infants Via Azithromycin for Neonates Trial
Antibiotic Therapy in Viral Airway Infections
Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds
Prospective Observational Study to Characterize Patients Treated at Internal Medicine Clinics
Genetic Susceptibility to Severe Infections
Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean